Written Question·Department of Health and Social Care·UIN 43867

Voluntary Scheme for Branded Medicines Pricing, Access and Growth

Tabled: 3 April 2025

Answered: 9 April 2025

Question

Dame Chi Onwurah

Labour — Newcastle upon Tyne Central and West

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the repayment rate for newer medicines under the Voluntary Scheme for Branded Medicines Pricing, Access and Growth on the UK life sciences sec

Answer

Ashley Dalton

The voluntary scheme for branded medicines pricing, access, and growth (VPAG) is a unique partnership between the Government and the pharmaceutical industry and includes a range of commitments to support innovation and improve National Health Service acce...

ⓘ

This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 43867) →